Study shows vitamin E can help certain diabetics avoid heart attacks
NEW YORK Vitamin E supplements can significantly reduce the risk of heart attacks and related deaths for diabetics who carry a particular version of a gene, according to a report released Friday by researchers at the Technion-Israel Institute of Technology and the Clalit Health Services in Israel.
After 18 months of treatment, people with the haptoglobin 2-2 gene who took 400 International Units of vitamin E daily had more than 50 percent fewer heart attacks, strokes and related deaths than Hp 2-2 patients who took a placebo pill. As many as 40 percent of diabetics carry the Hp 2-2 gene.
The findings were published in the November 21 online edition of the journal Arteriosclerosis, Thrombosis, and Vascular Biology.
Most of the difference came from the reduced number of heart attacks among those taking vitamin E. In the group of 1,434 Hp 2-2 individuals taking part in the study, seven people had a heart attack, compared to 17 who did not take the vitamin. Dr. Andrew Levy, of the Technion Faculty of Medicine, said there were no side effects observed in patients who took vitamin E.
The study suggests that genetic testing for Hp 2-2 “may be useful to identify a large group of diabetes individuals who could potentially derive cardiovascular benefit from a very inexpensive treatment,” Levy said.
Jason Ash named PacificHealth president and CEO
MATAWAN, N.J. PacificHealth Laboratories on Thursday named Jason Ash as the company’s president and chief operating officer, as well as a member of the company’s board, effective Jan. 3.
Ash assumes the role of president from Portman, who will continue to serve as chief executive officer, chief scientific officer and chairman.
“Jason brings a great deal of knowledge and experience in the performance beverage arena, and actually led Cadbury’s negotiations leading to their acquisition of the Accelerade and Endurox trade marks and intellectual property,” Portman stated. “Jason’s existing knowledge of our company and our growth objectives will enable him to hit the ground running and provides an excellent opportunity for PacificHealth to rapidly expand upon our existing growth strategy.”
Ash also assumes chief operating officer duties currently held by Stephen Kuchen, who will continue to serve as chief financial officer, treasurer, secretary and director.
Ash brings a decade worth of experience in commercial brand management and consumer marketing to PacificHealth, most recently serving as general manager and vice president of Cadbury Schweppes Americas Beverages Sports in the energy and water category unit.
Next announces results of Nexrutine dietary supplement study
SALINAS, Calif. Next Pharmaceuticals announced Thursday the results of a clinical study on Nexrutine, conducted at The LaValle Metabolic Institute in Cincinnati.
The study concluded that Nexrutine, when used as a dietary supplement, helps in the management of pain and/or inflammation and helps promote a restful sleep with minimal side effects.
“Suffering from pain and inflammation can be a life-changing challenge,” stated Jim LaValle, founder of The LaValle Metabolic Institute and author of many books, including Cracking the Metabolic Code and the Cox-2 Connection. “Many of our patients are relieved to find a natural remedy that is not only cardio protective, but unlike aspirin, is easy on the stomach. This study demonstrates that Nexrutine has an excellent safety profile.”
Out of the 401 participants in the study, 92 percent reported Nexrutine provided pain relief and 93 percent reported improvement in their overall condition.
Nexrutine is a proprietary blend of natural ingredients developed to address general aches and pains associated with physical activity and over-exertion.
The clinical trial was designed to be an open label, single center, clinical trial.